 |
|
 |
| Thai Select by Thai Trade |
|
|
 |
|
|
|
|
|
|
|
|
|
ขณะนี้มี, 131 บุคคลทั่วไป เข้าใช้โปรแกรม
ท่านยังไม่ได้ลงทะเบียนเป็นสมาชิก หากท่านต้องการ กรุณาสมัครฟรีได้ที่นี่
|
|
|
|
|
|
|
|
Import/Export Forum
Find Thai importers/exporters, sell and buy your products from members for free.
www.IEForum.com
Thai CD Express
Thai Music, VCD movies/karaokes. We ship worldwide. Visit us NOW.
www.thaicdexpress.com
Advertise with Us!
Reach 40,000+ people per month. โฆษณากับเราถึงผู้อ่านกว่า 40,000 คน/เดือน
www.ThaiNewYork.com
|
|
|
|
|
 |
|
|
|
BANGKOK, Thailand: Thailand's new government will review its predecessor's decision to ignore patents on several cancer-fighting drugs, a move that allowed cheaper generic versions to be imported and manufactured, a government statement said Saturday.
On Jan. 4, less than a month before leaving office, the government of former Prime Minister Surayud Chulanont issued so-called "compulsory licenses" for four anti-cancer drugs, effectively depriving the drugs' license holders of patent protection in Thailand.
The object of compulsory licensing was to make some drugs more affordable by taking away the patent holder's ability to control the drug's price, a benefit of being a drug's exclusive supplier.
According to international trade rules, a government may issue a compulsory license to manufacture a generic drug only in case of a national public health emergency.
In the past two years, the Thai government has issued compulsory licenses for several other drugs used to treat HIV/AIDS and heart disease rare but not unprecedented actions that drew criticism from companies owning patents on the drugs.
The companies dispute whether the circumstances in Thailand qualify as a national public health emergency.
Public Health Minister Chaiya Sasomsup, who was sworn in Wednesday, said the planned review did not necessarily mean the compulsory licenses would be revoked, according to the statement from his ministry.
Chaiya told reporters that the decision to review the licenses came after his ministry received a letter from the Commerce Ministry saying that U.S. drug manufacturers might ask Washington to apply trade sanctions against Thailand because it had issued compulsory licenses.
Although Chaiya insisted that the decision to review the compulsory licenses did not mean certain revocation, it raised concerns among patients and activists.
"We are definitely worried that trade will take priority, and not human lives," said Nimit Tien-udom, director of the AIDS Access Foundation. "He shouldn't announce this until he can come up with a better alternative that will guarantee access to medicines for poor patients."
The four drugs covered by the Jan. 4 ruling are Novartis' imatinib, used to treat leukemia and gastrointestinal tumors, and letrozole, used to treat breast cancer; Sanofi-Aventis' docetaxel, used to treat lung and breast cancer; and Roche's erlotinib.
Novartis and Roche are Swiss, and Sanofi-Aventis is French.
[แสดงความเห็น? | ส่งให้เพื่อนอ่าน | หน้าสำหรับพิมพ์]
|
|
|
|
|
| |
|
|
|
| ข้อมูลเชื่อมโยงที่เกี่ยวข้อง |
|
|
|
|
|
|
|
| Thailand to review decision to break patents on cancer drugs | เรียกเข้าระบบ หรือ ลงทะเบียน | 0 ความเห็น |
|
| | ความเห็นเป็นของผู้ส่งเข้ามา ทางเราไม่สามารถรับผิดชอบต่อความเห็นนั้นๆได้ |
| |
| |
|
